Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

Chris Mahony, Lynda Erskine, Jennifer Niven, Nigel H Greig, William Douglas Figg, Neil Vargesson (Corresponding Author)

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers. An additional analog, Pomalidomide, has recently been licensed for treatment of multiple myeloma, and is purported to be clinically more potent than either Thalidomide or Lenalidomide. Using a combination of zebrafish and chicken embryos together with in vitro assays we have determined the relative anti-inflammatory activity of each compound. We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflammatory agent than either Thalidomide or Lenalidomide. We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogenesis, and neurite outgrowth, known detrimental effects of Thalidomide. We found that Pomalidomide, displays a high degree of cell specificity, and has no detectable teratogenic, antiangiogenic or neurotoxic effects at potent anti-inflammatory concentrations. This is in marked contrast to Thalidomide and Lenalidomide, which had detrimental effects on blood vessels, nerves, and embryonic development at anti-inflammatory concentrations. This work has implications for Pomalidomide as a treatment for conditions Thalidomide and Lenalidomide treat currently.
Original languageEnglish
Pages (from-to)12703-12708
Number of pages6
JournalPNAS
Volume110
Issue number31
Early online date15 Jul 2013
DOIs
Publication statusPublished - 30 Jul 2013

Fingerprint

Thalidomide
Zebrafish
Chickens
Embryonic Structures
Anti-Inflammatory Agents
Multiple Myeloma
Teratogenesis
Leprosy
Embryonic Development
Blood Vessels
lenalidomide
pomalidomide
In Vitro Techniques
Neoplasms

Keywords

  • thalidomide
  • pomalidomide
  • lenalidomide
  • angiogenesis
  • inflammation
  • cytoskeleton
  • chick embryo
  • zebrafish embryo
  • CPS49
  • cox2
  • drug screening

Cite this

Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. / Mahony, Chris; Erskine, Lynda; Niven, Jennifer; Greig, Nigel H; Figg, William Douglas; Vargesson, Neil (Corresponding Author).

In: PNAS, Vol. 110, No. 31, 30.07.2013, p. 12703-12708.

Research output: Contribution to journalArticle

Mahony, Chris ; Erskine, Lynda ; Niven, Jennifer ; Greig, Nigel H ; Figg, William Douglas ; Vargesson, Neil. / Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. In: PNAS. 2013 ; Vol. 110, No. 31. pp. 12703-12708.
@article{a9c0c5fe4a39484ab6934b4cced33e75,
title = "Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro",
abstract = "Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers. An additional analog, Pomalidomide, has recently been licensed for treatment of multiple myeloma, and is purported to be clinically more potent than either Thalidomide or Lenalidomide. Using a combination of zebrafish and chicken embryos together with in vitro assays we have determined the relative anti-inflammatory activity of each compound. We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflammatory agent than either Thalidomide or Lenalidomide. We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogenesis, and neurite outgrowth, known detrimental effects of Thalidomide. We found that Pomalidomide, displays a high degree of cell specificity, and has no detectable teratogenic, antiangiogenic or neurotoxic effects at potent anti-inflammatory concentrations. This is in marked contrast to Thalidomide and Lenalidomide, which had detrimental effects on blood vessels, nerves, and embryonic development at anti-inflammatory concentrations. This work has implications for Pomalidomide as a treatment for conditions Thalidomide and Lenalidomide treat currently.",
keywords = "thalidomide, pomalidomide, lenalidomide, angiogenesis, inflammation, cytoskeleton, chick embryo, zebrafish embryo, CPS49, cox2, drug screening",
author = "Chris Mahony and Lynda Erskine and Jennifer Niven and Greig, {Nigel H} and Figg, {William Douglas} and Neil Vargesson",
year = "2013",
month = "7",
day = "30",
doi = "10.1073/pnas.1307684110",
language = "English",
volume = "110",
pages = "12703--12708",
journal = "PNAS",
issn = "0027-8424",
publisher = "NATL ACAD SCIENCES",
number = "31",

}

TY - JOUR

T1 - Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

AU - Mahony, Chris

AU - Erskine, Lynda

AU - Niven, Jennifer

AU - Greig, Nigel H

AU - Figg, William Douglas

AU - Vargesson, Neil

PY - 2013/7/30

Y1 - 2013/7/30

N2 - Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers. An additional analog, Pomalidomide, has recently been licensed for treatment of multiple myeloma, and is purported to be clinically more potent than either Thalidomide or Lenalidomide. Using a combination of zebrafish and chicken embryos together with in vitro assays we have determined the relative anti-inflammatory activity of each compound. We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflammatory agent than either Thalidomide or Lenalidomide. We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogenesis, and neurite outgrowth, known detrimental effects of Thalidomide. We found that Pomalidomide, displays a high degree of cell specificity, and has no detectable teratogenic, antiangiogenic or neurotoxic effects at potent anti-inflammatory concentrations. This is in marked contrast to Thalidomide and Lenalidomide, which had detrimental effects on blood vessels, nerves, and embryonic development at anti-inflammatory concentrations. This work has implications for Pomalidomide as a treatment for conditions Thalidomide and Lenalidomide treat currently.

AB - Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers. An additional analog, Pomalidomide, has recently been licensed for treatment of multiple myeloma, and is purported to be clinically more potent than either Thalidomide or Lenalidomide. Using a combination of zebrafish and chicken embryos together with in vitro assays we have determined the relative anti-inflammatory activity of each compound. We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflammatory agent than either Thalidomide or Lenalidomide. We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogenesis, and neurite outgrowth, known detrimental effects of Thalidomide. We found that Pomalidomide, displays a high degree of cell specificity, and has no detectable teratogenic, antiangiogenic or neurotoxic effects at potent anti-inflammatory concentrations. This is in marked contrast to Thalidomide and Lenalidomide, which had detrimental effects on blood vessels, nerves, and embryonic development at anti-inflammatory concentrations. This work has implications for Pomalidomide as a treatment for conditions Thalidomide and Lenalidomide treat currently.

KW - thalidomide

KW - pomalidomide

KW - lenalidomide

KW - angiogenesis

KW - inflammation

KW - cytoskeleton

KW - chick embryo

KW - zebrafish embryo

KW - CPS49

KW - cox2

KW - drug screening

U2 - 10.1073/pnas.1307684110

DO - 10.1073/pnas.1307684110

M3 - Article

VL - 110

SP - 12703

EP - 12708

JO - PNAS

JF - PNAS

SN - 0027-8424

IS - 31

ER -